Corrigendum: Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study

Laura K. Ferris1 MD, PhD, Darrell S Rigel2 MD, Daniel M Siegel3 MD, Maral K Skelsey4 MD, Gary L. Peck5 MD, Catherine Hren6 MD, Christopher Gorman7 MD, Tana Frumento7 PAC, Burkhard Jansen8 MD, Zuxu Yao9 PhD, Jim Rock9 MS, Stevan R Knezevich10 MD PhD and Clay J Cockerell11 MD

Affiliations: 1Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 2Department of Dermatology, New York University Medical Center, New York, New York, USA, 3SUNY Downstate Medical Center, New York, New York, USA, 4Department of Dermatology, Georgetown University School of Medicine, Washington, District of Columbia, USA, 5Dermatologic Surgery Center of Washington, Chevy Chase, Maryland, USA, 6Cary Dermatology Center, Cary, North Carolina, USA, 7Avenues Dermatology, Richmond, Virginia, USA, 8Phoenix Skin, Phoenix, Arizona, USA, 9DermTech, La Jolla, California, USA, 10Pathology Associates, Clovis, California, USA, 11Cockerell Dermatopathology, Dallas, Texas, USA

Corresponding Author: Laura K. Ferris MD, PhD, Department of Dermatology, University of Pittsburgh, 3601 Fifth Avenue, Fifth Floor, Pittsburgh, PA 15238, Tel: 412-759-1914, Fax: 412-647-4832, Email: ferrislk@upmc.edu

The original article was published on May 15, 2019 and corrected on June 15, 2019.

The revised version of the article corrected Figure 2. This change appears in the revised online PDF copy of this article.